- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | AccuStem Sciences, Inc.: AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning | 277 | GlobeNewswire (Europe) | PHOENIX, Ariz. and LONDON, Sept. 17, 2025), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based... ► Artikel lesen | |
| 16.09. | AccuStem Sciences, Inc.: AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th | 226 | GlobeNewswire (Europe) | Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comPHOENIX and LONDON, Sept. 16, 2025), a clinical stage diagnostics... ► Artikel lesen | |
| 14.08. | Accustem Sciences Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 16.06. | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 206 | GlobeNewswire (Europe) | LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen | |
| 13.06. | AccuStem Sciences Chairman Gabriele Cerrone buys additional 8,991 shares | 3 | Seeking Alpha | ||
| 13.06. | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 225 | GlobeNewswire (Europe) | LONDON, June 13, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman... ► Artikel lesen | |
| ACCUSTEM SCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.05. | Accustem Sciences Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.04. | AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening | 354 | GlobeNewswire (Europe) | LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk... ► Artikel lesen | |
| 21.04. | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 223 | GlobeNewswire (Europe) | LONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen | |
| 16.04. | AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan | 306 | GlobeNewswire (Europe) | LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer... ► Artikel lesen | |
| 10.04. | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 261 | GlobeNewswire (Europe) | LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen | |
| 04.04. | AccuStem Sciences, Inc.: AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States | 362 | GlobeNewswire (Europe) | LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer... ► Artikel lesen | |
| 18.03. | AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test | 309 | GlobeNewswire (Europe) | AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026
LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:... ► Artikel lesen | |
| 03.01. | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 347 | GlobeNewswire (Europe) | LONDON and PHOENIX, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 91,30 | +1,22 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| MEDIGENE | 0,050 | -6,34 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 40,345 | -1,02 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| CUREVAC | 4,602 | -0,43 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 23,660 | +0,17 % | Watch Cigna, Moderna, Reddit, and More | ||
| VALNEVA | 3,958 | -1,54 % | Valneva-Aktie rückt zum Wochenstart in den Mittelpunkt - Marktteilnehmer bleiben wachsam! | ||
| EPIGENOMICS | 0,870 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 7,239 | -0,75 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 58,00 | +4,50 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 568,00 | +0,39 % | Aktien New York: Rekordrally setzt sich fort - Optimismus bei KI-Aktien | NEW YORK (dpa-AFX) - Die Rekordrally an den US-Börsen hat sich am Dienstag fortgesetzt. "Die KI-Party in New York geht weiter", kommentierte Christine Romar, Head of Europe beim Broker CMC Markets.... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,960 | -1,26 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,506 | +4,76 % | Defence Therapeutics Inc.: Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025 | Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| EDITAS MEDICINE | 2,725 | +1,49 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GENMAB | 246,90 | -0,36 % | H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB) |
ACCUSTEM SCIENCES INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACCUSTEM SCIENCES INC finden Sie auf Wallstreet Online.